Improving Long Term Treatment Outcomes in Age-Related Macular Degeneration

The Angiogenesis Foundation convened a national expert summit of top vision health experts focused on optimizing clinician utilization and long-term treatment outcomes in Age-Related Macular Degeneration (AMD). The Angiogenesis Foundation then convened an expert virtual roundtable allowing for an even larger group of leading vision health clinicians to provide an analysis of and further reflections on the summit’s findings. The clinicians were given a synopsis of the expert summit and then asked to provide their insights and contributions on the following topics:

  1. Real-world versus clinical trial settings and impact on long-term patient outcomes for anti-VEGF treatments for wet AMD.
  2. Variations in care, especially undertreatment, as a barrier to optimal long-term vision outcomes.
  3. Actions to improve long-term patient outcomes, including future research using real-world evidence (RWE).

This program is an audio archive of the expert virtual roundtable on improving long-term outcomes in exudative age-related macular degeneration.

As a supplement to the audio archive, a video animation and an in-depth white paper summarize the expert findings.

Click here to be taken to Supplemental Resources

TARGET AUDIENCE

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with age-related macular degeneration including: retina specialists, ophthalmologists, clinicians, nurses, health workers, patient advocates, caregivers, and low-vision services providers.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  1. Understand real-world versus clinical trial settings and impact on long-term patient outcomes for anti-VEGF treatments for wet AMD.
  2. Discuss variations in care, especially undertreatment, as a barrier to optimal long-term vision outcomes.
  3. Identify key actions to improve long-term patient outcomes, including future research using real-world evidence (RWE).

FACULTY

W. Lloyd Clark, M.D.
Palmetto Retina Center
W. Columbia, SC

Jeffrey Heier, M.D.
Ophthalmic Consultants of Boston
Boston, MA

William W. Li, M.D.
The Angiogenesis Foundation
Cambridge, MA

Quan Dong Nguyen, M.D., M.Sc.
Byers Eye Institute
Palo Alto, CA

John S. Pollack, M.D.
Rush University Medical Center
Chicago, IL

Charles C. Wykoff, M.D., Ph.D.
Retina Consultants of Houston
Houston, TX

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
W. Lloyd Clark, M.D.

Consultant/Advisor: F. Hoffmann-La Roche Ltd; Genentech, Inc; McKesson Corporation; Regeneron Pharmaceuticals, Inc.; Santen Pharmaceutical Co., Ltd.

Grant/Research Support: F. Hoffmann-La Roche Ltd; Genentech, Inc; Regeneron Pharmaceuticals, Inc.; Santen Pharmaceutical Co., Ltd.

Speakers’ Bureau: F. Hoffmann-La Roche Ltd; Genentech, Inc; Regeneron Pharmaceuticals, Inc.

Jeffrey Heier, M.D.

Consultant/Advisor: 4D Molecular Therapeutics; Adverum; ; Aerie Pharmaceuticals; Aerpio; Allegro Ophthalmics, LLC.; AsclepiX Therapeutics, LLC; Bayer AG; BVI; Chengdu Kanghong Pharmaceuticals Group Co., Ltd; Corcept Therapeutics; Daiichi Sankyo Company, Limited; F. Hoffmann-La Roche Ltd; Genentech, Inc; Heidelberg Pharma AG; Hemera Biosciences Inc; Janssen Pharmaceuticals, Inc; Kodiak Sciences Inc; Neurotech; Novartis AG; Ocular Therapeutix, Inc.; Quark; Regeneron Pharmaceuticals, Inc.; REGENXBIO Inc.; SciFluor Life Sciences; TLC Pharmaceutical Standards Ltd; Tyrogenex, Inc.

Grant/Research Support: Aerpio; Astellas Pharma Inc; Corcept Therapeutics; Daiichi Sankyo Company, Limited; F. Hoffmann-La Roche Ltd; Genentech, Inc; Genzyme Corporation; Hemera Biosciences Inc; Janssen Pharmaceuticals, Inc; Ophthotech Corporation; Optovue, Incorporated; Ra Pharmaceuticals, Inc; Regeneron Pharmaceuticals, Inc.; REGENXBIO Inc.; SciFluor Life Sciences; Shire; Stealth BioTherapeutics Inc.; ThromboGenics NV; TLC Pharmaceutical Standards Ltd; Tyrogenex, Inc.

William W. Li, M.D.

No relationships to disclose.

Quan Dong Nguyen, M.D., M.Sc.

Consultant/Advisor: AbbVie Inc; Genentech, Inc; Regeneron Pharmaceuticals, Inc.; Santen Pharmaceutical Co., Ltd.

Grant/Research Support: Genentech, Inc; Gilead; Regeneron Pharmaceuticals, Inc.; Santen Pharmaceutical Co., Ltd.

John S. Pollack, M.D.

Consultant/Advisor: Genentech, Inc; Notal Vision, Inc.

Grant/Research Support: Genentech, Inc

Charles C. Wykoff, M.D., Ph.D.

Consultant/Advisor: Alimera Sciences; Allergan; Bayer AG; Clearside Biomedical, Inc., D.O.R.C; F. Hoffmann-La Roche Ltd; Genentech, Inc; Novartis AG; Regeneron Pharmaceuticals, Inc.

Grant/Research Support: Allergan; Bayer AG; Clearside Biomedical, Inc., D.O.R.C; F. Hoffmann-La Roche Ltd; Genentech, Inc; Heidelberg Pharma AG; Novartis AG; Regeneron Pharmaceuticals, Inc.

Speakers’ Bureau: Allergan, Regeneron Pharmaceuticals, Inc.

Non-faculty: William Li, MD; Robert Mittman; Diana Saville; Jeffrey McRae; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and the Angiogenesis Foundation.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and the Angiogenesis Foundation. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, the Angiogenesis Foundation, and Regeneron Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.50 Non-physician
Course opens: 
05/31/2018
Course expires: 
05/30/2019
Rating: 
2

Available Credit

  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.50 Non-physician

Accreditation Period

Course opens: 
05/31/2018
Course expires: 
05/30/2019
Please login or register to take this course.